Corgentech Inc (Nasdaq: CGTK) today announced that the joint venture own originate treat patients surrounded by a multi-center Phase 1/2 clinical tribulation of its NF-kappaB Decoy (NF-kB Decoy) linctus participant all for the nursing of atopic dermatitis, a incurable crust illness also preset in place of eczema that affect nearly 15 million adults [...]
Entries from May 2009
Phase 1/2 Trial of New Drug Candidate for Eczema, Corgentech Treats First Patient
May 9th, 2009 · No Comments
Tags: best weight loss program
